{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:04:21Z","timestamp":1792785861669,"version":"4.5.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:00:00Z","timestamp":1626825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Academic Department of Blood Sciences"},{"DOI":"10.13039\/100009745","name":"Royal Devon and Exeter NHS Foundation Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009745","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Because of COVID-19 public health restrictions, telemedicine has replaced conventional outpatient follow up for most patients with chronic immune-mediated inflammatory disorders treated with biologic drugs. Innovative solutions to facilitate remote therapeutic drug monitoring are therefore required. Low-volume intracapillary blood sampling can be undertaken by patients at home and samples returned by post to central laboratories. We sought to report the effect of the COVID-19 pandemic on requests for therapeutic drug monitoring and the equivalence, acceptability and effectiveness of low volume Patient-led Remote IntraCapillary pharmacoKinetic Sampling [fingerPRICKS] compared to conventional venepuncture.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We undertook a cross-sectional blood sampling methods comparison study and compared sample types using linear regression models. Drug and antidrug antibody levels were measured using standard ELISAs. Acceptability was assessed using a purpose-designed questionnaire.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Therapeutic drug monitoring requests for adalimumab (96.5 [70.5\u2013106] per week to 52 [33.5\u201357.0], p &amp;lt; 0.001) but not infliximab (184.5 [161.2\u2013214.2] to 161 [135\u2013197.5], p = 0.34) reduced during the first UK stay-at-home lockdown compared with the preceding 6 months. Fingerprick sampling was equivalent to conventional venepuncture for adalimumab, infliximab, vedolizumab and ustekinumab drug, and anti-adalimumab and anti-infliximab antibody levels. The median [interquartile range] volume of serum obtained using intracapillary sampling was 195 \u00b5L [130\u2013210]. More than 87% [90\/103] of patients agreed that intracapillary testing was easy and 69% [71\/103] preferred it to conventional venepuncture. In routine care, 75.3% [58\/77] of patients returned two blood samples within 14 days to permit remote assessment of biologic therapeutic drug monitoring.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Therapeutic drug monitoring can be undertaken using patient-led remote intracapillary blood sampling and has the potential to be a key adjunct to telemedicine in patients with immune-mediated inflammatory diseases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjab128","type":"journal-article","created":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T07:31:45Z","timestamp":1626852705000},"page":"190-198","source":"Crossref","is-referenced-by-count":18,"title":["Patient-led Remote IntraCapillary pharmacoKinetic Sampling (fingerPRICKS) for Therapeutic Drug Monitoring in patients with Inflammatory Bowel Disease"],"prefix":"10.1093","volume":"16","author":[{"given":"Desmond","family":"Chee","sequence":"first","affiliation":[{"name":"Exeter Inflammatory Bowel Disease and Pharmacogenetics Group, University of Exeter, Exeter, UK"},{"name":"Department of Gastroenterology, Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Nice","sequence":"additional","affiliation":[{"name":"Exeter Inflammatory Bowel Disease and Pharmacogenetics Group, University of Exeter, Exeter, UK"},{"name":"Department of Biochemistry, Exeter Clinical Laboratory International, Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Hamilton","sequence":"additional","affiliation":[{"name":"Exeter Inflammatory Bowel Disease and Pharmacogenetics Group, University of Exeter, Exeter, UK"},{"name":"Department of Gastroenterology, Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Jones","sequence":"additional","affiliation":[{"name":"University of Bath, Bath, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Hawkins","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Redstone","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vida","family":"Cairnes","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Pohl","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Chanchlani","sequence":"additional","affiliation":[{"name":"Exeter Inflammatory Bowel Disease and Pharmacogenetics Group, University of Exeter, Exeter, UK"},{"name":"Department of Gastroenterology, Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4201-4879","authenticated-orcid":false,"given":"Simeng","family":"Lin","sequence":"additional","affiliation":[{"name":"Exeter Inflammatory Bowel Disease and Pharmacogenetics Group, University of Exeter, Exeter, UK"},{"name":"Department of Gastroenterology, Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas A","family":"Kennedy","sequence":"additional","affiliation":[{"name":"Exeter Inflammatory Bowel Disease and Pharmacogenetics Group, University of Exeter, Exeter, UK"},{"name":"Department of Gastroenterology, Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariq","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Exeter Inflammatory Bowel Disease and Pharmacogenetics Group, University of Exeter, Exeter, UK"},{"name":"Department of Gastroenterology, Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R","family":"Goodhand","sequence":"additional","affiliation":[{"name":"Exeter Inflammatory Bowel Disease and Pharmacogenetics Group, University of Exeter, Exeter, UK"},{"name":"Department of Gastroenterology, Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J","family":"McDonald","sequence":"additional","affiliation":[{"name":"Exeter Inflammatory Bowel Disease and Pharmacogenetics Group, University of Exeter, Exeter, UK"},{"name":"Department of Biochemistry, Exeter Clinical Laboratory International, Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,7,21]]},"reference":[{"key":"2022022311191215000_CIT0001","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2468-1253(19)30012-3","article-title":"Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn\u2019s disease: a prospective, multicentre, cohort study","volume":"4","author":"Kennedy","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2022022311191215000_CIT0002","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/ecco-jcc\/jjaa029","article-title":"Is therapeutic drug monitoring for anti-tumour necrosis factor agents in adults with inflammatory bowel disease ready for standard of care? A systematic review and meta-analysis","volume":"14","author":"Shah","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2022022311191215000_CIT0003","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1093\/ecco-jcc\/jjaa092","article-title":"Therapeutic drug monitoring of anti-tumour necrosis factor agents in inflammatory bowel diseases: the jury is still out","volume":"14","author":"Agrawal","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2022022311191215000_CIT0004","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S2468-1253(20)30126-6","article-title":"Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis","volume":"5","author":"Mao","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2022022311191215000_CIT0005","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.jaip.2020.03.008","article-title":"Telemedicine in the era of COVID-19","volume":"8","author":"Portnoy","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2022022311191215000_CIT0006","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1038\/s41591-020-01144-1","article-title":"Will patient-centric sampling become the norm for clinical trials after COVID-19?","volume":"26","author":"James","year":"2020","journal-title":"Nat Med"},{"key":"2022022311191215000_CIT0007","volume-title":"WHO Guidelines on Drawing Blood: Best Practices in Phlebotomy","year":"2010","edition":"7"},{"key":"2022022311191215000_CIT0008","article-title":"Incidence and prevalence of inflammatory bowel disease in Devon, UK","author":"Hamilton","year":"2020","journal-title":"Frontline Gastroenterol"},{"key":"2022022311191215000_CIT0009","volume-title":"Assessment of Equivalence or Suitability of Specimen Types for Medical Laboratory Measurement Procedures","author":"CLSI","year":"2019","edition":"1"},{"key":"2022022311191215000_CIT0010","first-page":"55","article-title":"A technique for the measurement of attitudes","volume":"22","author":"Likert","year":"1932","journal-title":"Arch Psychol"},{"key":"2022022311191215000_CIT0011","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"2022022311191215000_CIT0012","author":"Ministry of Housing Comunities and Local Government"},{"key":"2022022311191215000_CIT0013","doi-asserted-by":"crossref","first-page":"5A","DOI":"10.1155\/2005\/269076","article-title":"Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology","volume":"19 Suppl A","author":"Silverberg","year":"2005","journal-title":"Can J Gastroenterol"},{"key":"2022022311191215000_CIT0014"},{"key":"2022022311191215000_CIT0015","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1177\/0004563215580001","article-title":"Infliximab and adalimumab are stable in whole blood clotted samples for seven days at room temperature","volume":"52","author":"Perry","year":"2015","journal-title":"Ann Clin Biochem"},{"key":"2022022311191215000_CIT0016","author":"Immunodiagnostik","year":"2015"},{"key":"2022022311191215000_CIT0017","author":"Immunodiagnostik","year":"2015"},{"key":"2022022311191215000_CIT0018","author":"Immunodiagnostik","year":"2015"},{"key":"2022022311191215000_CIT0019","author":"Immunodiagnostik","year":"2015"},{"key":"2022022311191215000_CIT0020","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/apt.15113","article-title":"Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation","volume":"49","author":"Osterman","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2022022311191215000_CIT0021","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1053\/j.gastro.2018.01.043","article-title":"Pharmacokinetics and exposure response relationships of ustekinumab in patients with Crohn\u2019s disease","volume":"154","author":"Adedokun","year":"2018","journal-title":"Gastroenterology"},{"key":"2022022311191215000_CIT0022","article-title":"Disease monitoring of biologic treatment in IBD: early impact and future implications of COVID-19 pandemic","author":"Shields","year":"2020","journal-title":"Frontline Gastroenterol"},{"key":"2022022311191215000_CIT0023","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/ygh2.433","article-title":"The effects of COVID-19 on IBD prescribing and service provision in a UK tertiary centre","volume":"2","author":"Sharma","year":"2020","journal-title":"GastroHep"},{"key":"2022022311191215000_CIT0024","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2021.02.068","article-title":"Randomized controlled trial: subcutaneous vs intravenous infliximab CT-P13 maintenance in inflammatory bowel disease","author":"Schreiber","year":"2021","journal-title":"Gastroenterology"},{"key":"2022022311191215000_CIT0025","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1053\/j.gastro.2020.05.063","article-title":"Innovation in inflammatory bowel disease care during the COVID-19 pandemic: results of a global telemedicine survey by the International Organization for the study of inflammatory bowel disease","volume":"159","author":"Lees","year":"2020","journal-title":"Gastroenterology"},{"key":"2022022311191215000_CIT0026","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/apt.12030","article-title":"Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays","volume":"36","author":"Vande Casteele","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"2022022311191215000_CIT0027","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1053\/j.gastro.2004.01.063","article-title":"Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences","volume":"126","author":"Loftus","year":"2004","journal-title":"Gastroenterology"},{"key":"2022022311191215000_CIT0028","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.dld.2019.01.024","article-title":"Impact of inflammatory bowel diseases on working life: a French nationwide survey","volume":"51","author":"Le Berre","year":"2019","journal-title":"Dig Liver Dis"},{"key":"2022022311191215000_CIT0029","doi-asserted-by":"crossref","first-page":"S281","DOI":"10.1093\/ecco-jcc\/jjy222.479","article-title":"P355 Diagnostic accuracy and usability of home calprotectin testing","volume":"13","author":"Thomas","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2022022311191215000_CIT0030","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1208\/s12248-018-0282-x","article-title":"Golimumab dried blood spot analysis (GOUDA): a prospective trial showing excellent correlation with venepuncture samples and more detailed pharmacokinetic information","volume":"21","author":"Detrez","year":"2018","journal-title":"AAPS J"},{"key":"2022022311191215000_CIT0031","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1111\/bcp.13939","article-title":"Dried blood samples can support monitoring of infliximab concentrations in patients with inflammatory bowel disease: a clinical validation","volume":"85","author":"Berends","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"2022022311191215000_CIT0032","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/FTD.0000000000000686","article-title":"Monitoring of adalimumab concentrations at home in patients with inflammatory bowel disease using dried blood samples","volume":"42","author":"Berends","year":"2020","journal-title":"Ther Drug Monit"},{"key":"2022022311191215000_CIT0033","article-title":"Infliximab level between venous and capillary blood using novel device strongly correlate in paediatric IBD patients","author":"Zijlstra","year":"2020","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2022022311191215000_CIT0034","doi-asserted-by":"crossref","first-page":"113224","DOI":"10.1016\/j.jpba.2020.113224","article-title":"Evaluating an easy sampling method using dried blood spots to determine vedolizumab concentrations","volume":"185","author":"Bian","year":"2020","journal-title":"J Pharm Biomed Anal"},{"key":"2022022311191215000_CIT0035","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/apt.13757","article-title":"Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays","volume":"44","author":"Afonso","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"2022022311191215000_CIT0036","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s40262-014-0177-7","article-title":"Therapeutic drug monitoring by dried blood spot: progress to date and future directions","volume":"53","author":"Wilhelm","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"2022022311191215000_CIT0037","doi-asserted-by":"crossref","first-page":"113597","DOI":"10.1016\/j.jpba.2020.113597","article-title":"Quantitative microsampling for bioanalytical applications related to the SARS-CoV-2 pandemic: usefulness, benefits and pitfalls","volume":"191","author":"Protti","year":"2020","journal-title":"J Pharm Biomed Anal"},{"key":"2022022311191215000_CIT0038","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1373\/clinchem.2015.247668","article-title":"Effect of dried blood spot quality on newborn screening analyte concentrations and recommendations for minimum acceptance criteria for sample analysis","volume":"62","author":"George","year":"2016","journal-title":"Clin Chem"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjab128\/41094282\/jjab128.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/16\/2\/190\/42580900\/jjab128.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/16\/2\/190\/42580900\/jjab128.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T08:39:35Z","timestamp":1645605575000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/16\/2\/190\/6325142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,21]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,7,21]]},"published-print":{"date-parts":[[2022,2,23]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab128","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,2,1]]},"published":{"date-parts":[[2021,7,21]]}}}